BetterLife Pharma - CEO, Ahmad Doroudian.
CEO, Ahmad Doroudian.
Source: BetterLife Pharma.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BetterLife Pharma Inc. (BETR) has received funding for its joint research with Carleton University into the use of its TD-010 compound to treat chronic anxiety
  • The compound would be marketed as a replacement for the highly dependent benzodiazepines often used to treat mood disorders
  • The partners have received funding from the Accelerate program at Mitacs, a non-profit organization committed to supporting new research partnerships
  • BetterLife Pharma is a biotechnology company that engages in the development and commercialization of psychedelic products for the treatment of mental disorders
  • BetterLife Pharma Inc. (BETR) is up 1.75 per cent, trading at $0.29 per share

BetterLife Pharma (BETR) has received funding for its joint research with Carleton University into the use of TD-010 to treat chronic anxiety and depression.

TD-010, or dihydrohonokiol-B, is a compound that BetterLife is developing as a replacement for benzodiazepine in the treatment of anxiety.

Benzodiazepines are among the most used anxiolytic therapeutics, but have drawbacks including treatment resistance, dependence, and serious side effects.

BetterLife is working with Dr. Argel Aguilar-Valles at the Carleton University Department of Neuroscience to test TD-010 in order to understand its long-term effects and effectiveness.

Dr. Ahmad Doroudian, CEO of BetterLife, commented on the research partnership.

“BetterLife’s goal is to bring this treatment to the Investigational New Drug (IND) application and the clinic as soon as possible because it is non-addictive yet potentially highly effective,” he said.

The partners have received funding from the Accelerate program at Mitacs, a non-profit organization committed to supporting new research partnerships.

Dr. Argel Aguilar-Valles commented,

“We are delighted to have the opportunity to examine TD-010 in our established animal anxiety models. [. . .] TD-010 can be a promising alternative in the treatment of chronic anxiety.”

BetterLife Pharma is a biotechnology company that engages in the development and commercialization of psychedelic products for the treatment of mental disorders.

BetterLife Pharma Inc. (BETR) is up 1.75 per cent, trading at $0.29 per share as of 9:36 am ET.

More From The Market Herald
Rakovina Therapeutics Inc. (TSXV:RKV) - Executive Chairman- Jeffrey Bacha.

" Rakovina (TSXV:RKV) advancing trial programs for cancer treatment

Rakovina Therapeutics (RKV) is advancing its programs for malignant tumour treatment therapies.
MedMira Inc. - CEO, Hermes Chan

" MedMira (TSXV:MIR) gets CE mark during new device regulations

MedMira Inc. (MIR) has received the CE mark for three of seven products submitted this year.
The Market Herald Video

" Empower Clinics (CSE:CBDT) accredited for Covid-19 mobile testing in B.C.

Empower Clinics (CBDT) has received accreditation for its COVID-19 mobile testing solutions.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.